San Francisco Bay Area biotech stories.
Monday, July 30, 2012
Ultragenyx raises $15 million
Ultragenyx Prsident and CEO Emil Kakkis.
Orphan drug developer Ultragenyx Pharmaceutical Inc. has gathered $15.1 million toward a goal of raising $30.1 million, according to a Securities and Exchange Commission filing Monday.
The Novato company, started by former
BioMarin Pharmaceutical Inc.
Chief Medical Officer
won orphan drug designation for two drugs
from the Food and Drug Administration as well as from
European drug regulators
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)